PL1797038T3 - Termodynamicznie trwała postać tosylanu bay 43-9006 - Google Patents

Termodynamicznie trwała postać tosylanu bay 43-9006

Info

Publication number: PL1797038T3
Authority: PL; Poland
Prior art keywords: tosylate; bay; thermodynamically stable; stable form; thermodynamically
Prior art date: 2004-09-29

Application number

PL05797740T

Other languages

English (en)

Inventor

Alfons Grunenberg

Jana Lenz

Original Assignee

Bayer Healthcare Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-29

Filing date

2005-09-20

Publication date

2012-11-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35482258&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1797038(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-09-20 Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc

2012-11-30 Publication of PL1797038T3 publication Critical patent/PL1797038T3/pl

Links

IVDHYUQIDRJSTI-UHFFFAOYSA-N sorafenib tosylate Chemical compound [H+].CC1=CC=C(S([O-])(=O)=O)C=C1.C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 IVDHYUQIDRJSTI-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Glass Compositions (AREA)
Analysing Materials By The Use Of Radiation (AREA)
Catalysts (AREA)
Medicinal Preparation (AREA)
Paper (AREA)

PL05797740T 2004-09-29 2005-09-20 Termodynamicznie trwała postać tosylanu bay 43-9006 PL1797038T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP04023130		2004-09-29
EP05797740A EP1797038B1 (en)	2004-09-29	2005-09-20	Thermodynamically stable form of bay 43-9006 tosylate
PCT/EP2005/010119 WO2006034797A1 (en)	2004-09-29	2005-09-20	Thermodynamically stable form of bay 43-9006 tosylate

Publications (1)

Publication Number	Publication Date
PL1797038T3 true PL1797038T3 (pl)	2012-11-30

Family

ID=35482258

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL05797740T PL1797038T3 (pl)	2004-09-29	2005-09-20	Termodynamicznie trwała postać tosylanu bay 43-9006

Country Status (33)

Country	Link
US (1)	US8877933B2 (pl)
EP (1)	EP1797038B1 (pl)
JP (2)	JP5215666B2 (pl)
KR (4)	KR101381454B1 (pl)
CN (1)	CN101065360B (pl)
AR (1)	AR051301A1 (pl)
AU (1)	AU2005289100B2 (pl)
BR (1)	BRPI0515946A (pl)
CA (1)	CA2581843C (pl)
CU (1)	CU20070068A7 (pl)
CY (1)	CY1113598T1 (pl)
DK (1)	DK1797038T3 (pl)
EC (1)	ECSP077356A (pl)
ES (1)	ES2387812T3 (pl)
GT (1)	GT200500270A (pl)
HK (1)	HK1114605A1 (pl)
HN (1)	HN2005000722A (pl)
HR (1)	HRP20120662T1 (pl)
IL (1)	IL181734A (pl)
MA (1)	MA28880B1 (pl)
MY (1)	MY176929A (pl)
NO (1)	NO344272B1 (pl)
NZ (1)	NZ553804A (pl)
PE (3)	PE20060699A1 (pl)
PL (1)	PL1797038T3 (pl)
PT (1)	PT1797038E (pl)
SG (1)	SG155996A1 (pl)
SI (1)	SI1797038T1 (pl)
TW (1)	TWI382016B (pl)
UA (1)	UA91520C2 (pl)
UY (1)	UY29144A1 (pl)
WO (1)	WO2006034797A1 (pl)
ZA (1)	ZA200702510B (pl)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ES2384160T3 (es)	1999-01-13	2012-07-02	Bayer Healthcare Llc	Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
JP4636486B2 (ja)	2002-02-11	2011-02-23	バイエル、ファーマシューテイカルズ、コーポレイション	脈管形成阻害活性を有するアリール尿素
US10653684B2 (en)	2002-02-11	2020-05-19	Bayer Healthcare Llc	Aryl ureas with angiogenisis inhibiting activity
US7557129B2 (en)	2003-02-28	2009-07-07	Bayer Healthcare Llc	Cyanopyridine derivatives useful in the treatment of cancer and other disorders
CA2526617C (en)	2003-05-20	2015-04-28	Bayer Pharmaceuticals Corporation	Diaryl ureas with kinase inhibiting activity
DE602004010407T2 (de)	2003-07-23	2008-10-16	Bayer Pharmaceuticals Corp., West Haven	Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
ES2387812T3 (es)	2004-09-29	2012-10-02	Bayer Pharma Aktiengesellschaft	Forma termodinámicamente estable del tosilato BAY 43-9006
JP5304241B2 (ja)	2005-03-07	2013-10-02	バイエル・ヘルスケア・エルエルシー	癌の処置用のオメガ−カルボキシアリール置換ジフェニルウレアを含む医薬組成物
JP2009513707A (ja)	2005-10-31	2009-04-02	バイエルヘルスケアリミティドライアビリティカンパニー	ジアリールウレア及び併用剤
AR062927A1 (es) *	2006-10-11	2008-12-17	Bayer Healthcare Ag	4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
JP2010509382A (ja) *	2006-11-14	2010-03-25	バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト	４−［４−（｛［４−クロロ−３−（トリフルオロメチル）フェニル］カルバモイル｝アミノ）−３−フルオロフェノキシ］−ｎ−メチルピリジン−２−カルボキサミドの多形ｉｉ
CN101220024A (zh) *	2007-12-11	2008-07-16	杜晓敏	一组抑制激酶的抗癌化合物
US8217061B2 (en)	2008-01-17	2012-07-10	Sicor Inc.	Polymorphs of sorafenib tosylate and sorafenib hemi-tosylate, and processes for preparation thereof
WO2009106825A1 (en) *	2008-02-27	2009-09-03	Cipla Limited	Polymorphs of sorafenib and salts thereof
WO2010079498A2 (en) *	2009-01-12	2010-07-15	Hetero Research Foundation	Novel polymorph of sorafenib tosylate
WO2010119306A1 (en) *	2009-04-15	2010-10-21	Fondazione Irccs Istituto Nazionale Dei Tumori	Use of multi-kinase inhibitors in the treatment of vascular hyperpermeability
EP2440531A2 (en) *	2009-06-12	2012-04-18	Ratiopharm GmbH	Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide
US8604208B2 (en)	2009-09-24	2013-12-10	Ranbaxy Laboratories Limited	Polymorphs of sorafenib acid addition salts
AU2010299483B2 (en)	2009-09-24	2014-08-28	Sun Pharmaceutical Industries Limited	Process for the preparation of sorafenib tosylate
WO2011058522A1 (en)	2009-11-12	2011-05-19	Ranbaxy Laboratories Limited	Sorafenib ethylsulfonate salt, process for preparation and use
WO2011076711A2 (en)	2009-12-23	2011-06-30	Ratiopharm Gmbh	Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide
CA2788146C (en)	2010-01-29	2014-11-25	Ranbaxy Laboratories Limited	Sorafenib dimethtyl sulphoxide solvate
AR081060A1 (es)	2010-04-15	2012-06-06	Bayer Schering Pharma Ag	Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
WO2012041987A1 (en)	2010-10-01	2012-04-05	Bayer Pharma Aktiengesellschaft	Substituted n-(2-arylamino)aryl sulfonamide-containing combinations
WO2012071425A1 (en)	2010-11-22	2012-05-31	Teva Pharmaceutical Industries Ltd.	Solid state forms of sorafenib besylate, and processes for preparations thereof
WO2013000909A1 (en)	2011-06-28	2013-01-03	Bayer Intellectual Property Gmbh	Topical ophthalmological pharmaceutical composition containing sorafenib
EP2559431A1 (en)	2011-08-17	2013-02-20	Ratiopharm GmbH	Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
EP2806860B1 (en)	2012-01-23	2023-04-19	Sandoz AG	Pharmaceutical composition containing crystalline sorafenib tosylate
US9156789B2 (en)	2012-05-21	2015-10-13	Hetero Research Foundation	Process for sorafenib tosylate polymorph III
WO2013175483A1 (en) *	2012-05-23	2013-11-28	Shilpa Medicare Limited	Process for preparing crystalline sorafenib tosylate
CN103570613B (zh)	2012-07-18	2016-06-15	苏州泽璟生物制药有限公司	氘代ω-二苯基脲或其盐的多晶型物
CN103896833B (zh) *	2012-12-27	2016-12-28	上海创诺制药有限公司	索拉非尼对甲苯磺酸盐溶剂化物多晶型物及其制法和用途
WO2014118807A1 (en) *	2013-02-04	2014-08-07	Intas Pharmaceuticals Limited	A novel process for the preparation of sorafenib tosylate form iii
WO2014138905A1 (en) *	2013-03-14	2014-09-18	Apotex Technologies Inc.	Forms of sorafenib tosylate and processes for the preparation thereof
US9765723B2 (en)	2013-05-10	2017-09-19	Denso Corporation	Fuel injection control device and fuel injection system
CN104761492A (zh) *	2014-01-03	2015-07-08	正大天晴药业集团股份有限公司	对甲苯磺酸索拉非尼的晶型及其制备方法
US20170114323A1 (en) *	2014-06-19	2017-04-27	Whitehead Institute For Biomedical Research	Uses of kinase inhibitors for inducing and maintaining pluripotency
CN104177292A (zh) *	2014-08-08	2014-12-03	亿腾药业（泰州）有限公司	一种工业化生产甲苯磺酸索拉非尼多晶型ⅰ的方法
CN105439947A (zh) *	2014-12-01	2016-03-30	石药集团中奇制药技术（石家庄）有限公司	一种甲苯磺酸索拉非尼新晶型及其制备方法
RU2568638C1 (ru) *	2015-02-26	2015-11-20	Индивидуальный предприниматель Михайлов Олег Ростиславович	КРИСТАЛЛИЧЕСКАЯ β-МОДИФИКАЦИЯ 4-[4-({ [4-ХЛОРО-3-(ТРИФТОРОМЕТИЛ) ФЕНИЛ]КАРБАМОИЛ} АМИНО)ФЕНОКСИ]-N-МЕТИЛ-ПИРИДИН-2-КАРБОКСАМИДА п-ТОЛУОЛСУЛЬФОНАТА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЁ ОСНОВЕ
EP3109236B1 (en)	2015-06-23	2017-08-09	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Scalable process for the preparation of sorafenib tosylate ethanol solvate and sorafenib tosylate form iii
CN106336377A (zh) *	2015-07-17	2017-01-18	苏州亚宝药物研发有限公司	一种甲苯磺酸索拉非尼晶型ⅱ的制备方法
CN105503715A (zh) *	2015-12-03	2016-04-20	神威药业集团有限公司	一种索拉非尼半甲苯磺酸盐多晶型及其制备方法
CN105585523A (zh) *	2015-12-29	2016-05-18	上海北卡医药技术有限公司	一种对甲苯磺酸索拉非尼的新晶型及其制备方法和用途
CN107759517A (zh) *	2016-08-23	2018-03-06	广州白云山医药集团股份有限公司白云山制药总厂	一种甲苯磺酸索拉非尼晶型ⅰ的制备方法
CN107840823B (zh) *	2016-09-20	2021-08-17	意大利合成制造有限公司	用于制备甲苯磺酸索拉非尼乙醇溶剂化物和iii型甲苯磺酸索拉非尼的可变规模的方法
CN108164459B (zh) *	2016-12-07	2021-07-27	上海创诺制药有限公司	甲苯磺酸索拉非尼晶型iii的制备方法
SI3565542T1 (sl)	2017-01-05	2024-08-30	Radius Pharmaceuticals, Inc.	Polimorfne oblike RAD1901-2HCL
CN109796400B (zh) *	2017-11-16	2022-07-29	四川科伦药物研究院有限公司	一种甲苯磺酸索拉菲尼晶型及其制备方法
US11179322B2 (en)	2018-07-10	2021-11-23	Novocure Gmbh	Methods and compositions for treating tumors with TTFields and sorafenib
WO2018211336A2 (en)	2018-09-07	2018-11-22	Alvogen Malta Operations (Row) Ltd	Solid dosage form containing sorafenib tosylate
US20210401859A1 (en)	2018-11-01	2021-12-30	Syros Pharmaceuticals, Inc.	Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
CN110156671A (zh) *	2019-06-06	2019-08-23	杭州中美华东制药有限公司	新型的索拉非尼共晶及其制备方法
AU2020326612A1 (en)	2019-08-02	2022-03-17	Onehealthcompany, Inc.	Treatment of canine cancers
CN117088809A (zh) *	2022-05-12	2023-11-21	浙江工业大学	一种索拉非尼-丙二酸共晶及其制备方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CO4410191A1 (es)	1994-09-19	1997-01-09	Lilly Co Eli	SINTESIS DE 3-[4-(2-AMINOETOXI)BENZOIL]-2-ARIL-6- HIDROXIBENZO [b] TIOFENOS
US5629425A (en) *	1994-09-19	1997-05-13	Eli Lilly And Company	Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
WO1997046526A1 (en) *	1996-06-07	1997-12-11	Eisai Co., Ltd.	Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
ID21924A (id)	1996-09-23	1999-08-12	Lilly Co Eli	Olanzapin dihidrat d
US6344476B1 (en) *	1997-05-23	2002-02-05	Bayer Corporation	Inhibition of p38 kinase activity by aryl ureas
US6187799B1 (en) *	1997-05-23	2001-02-13	Onyx Pharmaceuticals	Inhibition of raf kinase activity using aryl ureas
US7329670B1 (en) *	1997-12-22	2008-02-12	Bayer Pharmaceuticals Corporation	Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en) *	1997-12-22	2009-04-14	Bayer Pharmaceuticals Corporation	Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
ES2384160T3 (es)	1999-01-13	2012-07-02	Bayer Healthcare Llc	Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
WO2000042012A1 (en)	1999-01-13	2000-07-20	Bayer Corporation	φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US7928239B2 (en) *	1999-01-13	2011-04-19	Bayer Healthcare Llc	Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
ME00275B (me) *	1999-01-13	2011-02-10	Bayer Corp	ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
US8124630B2 (en) *	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7235576B1 (en) *	2001-01-12	2007-06-26	Bayer Pharmaceuticals Corporation	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en)	2001-04-20	2008-05-13	Bayer Pharmaceuticals Corporation	Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
ES2391382T3 (es) *	2001-12-03	2012-11-23	Bayer Healthcare Llc	Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
GB0129876D0 (en)	2001-12-13	2002-02-06	Smithkline Beecham Plc	Novel pharmaceutical
US20030207872A1 (en) *	2002-01-11	2003-11-06	Bayer Corporation	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AU2003209119A1 (en) *	2002-02-11	2003-09-04	Bayer Pharmaceuticals Corporation	Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
JP4636486B2 (ja) *	2002-02-11	2011-02-23	バイエル、ファーマシューテイカルズ、コーポレイション	脈管形成阻害活性を有するアリール尿素
CA2475818C (en) *	2002-02-11	2011-07-19	Bayer Pharmaceuticals Corporation	Aryl ureas as kinase inhibitors
GB0203412D0 (en)	2002-02-13	2002-04-03	Pharmagene Lab Ltd	5-HT 2B receptor antagonists
WO2003088228A1 (fr)	2002-03-29	2003-10-23	Sony Corporation	Dispositif d'identification de disque optique, procede d'identification de disque optique, enregistreur de disque optique, et dispositif de reproduction de disque optique
DE60318035T2 (de) *	2002-05-03	2008-12-11	Janssen Pharmaceutica N.V.	Polymermikroemulsionen
US7351534B2 (en) *	2003-01-27	2008-04-01	Oregon Health & Sciences University	Gene mutation associated with age-related macular degeneration
US7557129B2 (en) *	2003-02-28	2009-07-07	Bayer Healthcare Llc	Cyanopyridine derivatives useful in the treatment of cancer and other disorders
US7378233B2 (en) *	2003-04-12	2008-05-27	The Johns Hopkins University	BRAF mutation T1796A in thyroid cancers
CA2526617C (en) *	2003-05-20	2015-04-28	Bayer Pharmaceuticals Corporation	Diaryl ureas with kinase inhibiting activity
DE602004010407T2 (de) *	2003-07-23	2008-10-16	Bayer Pharmaceuticals Corp., West Haven	Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
WO2005110994A2 (en) *	2004-04-30	2005-11-24	Bayer Pharmaceuticals Corporation	Substituted pyrazolyl urea derivatives useful in the treatment of cancer
ES2306216T3 (es) *	2004-08-27	2008-11-01	Bayer Pharmaceuticals Corporation	Composiciones farmaceuticas en forma de dispersiones solidas para el tratamiento de cancer.
MY191349A (en) *	2004-08-27	2022-06-17	Bayer Pharmaceuticals Corp	New pharmaceutical compositions for the treatment of hyper-proliferative disorders
ES2387812T3 (es)	2004-09-29	2012-10-02	Bayer Pharma Aktiengesellschaft	Forma termodinámicamente estable del tosilato BAY 43-9006
PT1797037E (pt) *	2004-09-29	2015-03-17	Bayer Healthcare Llc	Processo para a preparação de 4-{4-[({[4-cloro-3- (trifluorometil)-fenil]-amino}-carbonil)-amino]-fenoxi}-nmetilpiridina- 2-carboxamida
US7271763B2 (en) *	2005-03-03	2007-09-18	The United States Of America As Represented By The Secretary Of The Army	Hybrid-phased communication array
JP5304241B2 (ja)	2005-03-07	2013-10-02	バイエル・ヘルスケア・エルエルシー	癌の処置用のオメガ−カルボキシアリール置換ジフェニルウレアを含む医薬組成物
CA2627873A1 (en) *	2005-10-31	2007-05-10	Scott Wilhelm	Treatment of cancer with sorafenib
US8329408B2 (en) *	2005-10-31	2012-12-11	Bayer Healthcare Llc	Methods for prognosis and monitoring cancer therapy
AU2006312714A1 (en) *	2005-11-10	2007-05-18	Bayer Schering Pharma Aktiengesellschaft	Diaryl urea for treating pulmonary hypertension
JP2009515978A (ja) *	2005-11-14	2009-04-16	バイエルヘルスケアエルエルシー	Ｋｉｔ阻害剤に対する獲得耐性を伴う癌の治療
AR062927A1 (es) *	2006-10-11	2008-12-17	Bayer Healthcare Ag	4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
JP2010509253A (ja) *	2006-11-09	2010-03-25	バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト	４−［４−（｛［４−クロロ−３−（トリフルオロメチル）フェニル］カルバモイル｝アミノ）−３−フルオロフェノキシ］−ｎ−メチルピリジン−２−カルボキサミドの多形ｉｉｉ
JP2010509382A (ja) *	2006-11-14	2010-03-25	バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト	４−［４−（｛［４−クロロ−３−（トリフルオロメチル）フェニル］カルバモイル｝アミノ）−３−フルオロフェノキシ］−ｎ−メチルピリジン−２−カルボキサミドの多形ｉｉ
ATE498620T1 (de) *	2006-12-20	2011-03-15	Bayer Healthcare Llc	4-ä4-ä(ä3-tert-butyl-1-ä3-(hydroxymethyl)-pheny ü-1h-pyrazol-5-ylü-carbamoyl)-aminoü-3- fluorophenoxyü -n-methylpyridin-2-carboxamid sowie prodrugs und salze davon zur behandlung von krebs
CA2675979A1 (en) *	2007-01-19	2008-07-24	Bayer Healthcare Llc	Treatment of cancers having resistance to chemotherapeutic agents
ES2429107T3 (es) *	2007-01-19	2013-11-13	Bayer Healthcare Llc	Tratamiento de cánceres con una resistencia adquirida a los agentes inhibidores de KIT
US8217061B2 (en) *	2008-01-17	2012-07-10	Sicor Inc.	Polymorphs of sorafenib tosylate and sorafenib hemi-tosylate, and processes for preparation thereof
US20110257035A1 (en) *	2008-10-21	2011-10-20	Bayer Healthcare Llc	Identification of signature genes associated with hepatocellular carcinoma
AR081060A1 (es) *	2010-04-15	2012-06-06	Bayer Schering Pharma Ag	Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
US20130183268A1 (en) *	2010-07-19	2013-07-18	Bayer Healthcare Llc	Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2012041987A1 (en) *	2010-10-01	2012-04-05	Bayer Pharma Aktiengesellschaft	Substituted n-(2-arylamino)aryl sulfonamide-containing combinations
CA2840329A1 (en)	2011-06-28	2013-01-03	Bayer Healthcare Llc	Topical ophthalmological pharmaceutical composition containing regorafenib
WO2013000909A1 (en)	2011-06-28	2013-01-03	Bayer Intellectual Property Gmbh	Topical ophthalmological pharmaceutical composition containing sorafenib

2005
- 2005-09-20 ES ES05797740T patent/ES2387812T3/es active Active
- 2005-09-20 PL PL05797740T patent/PL1797038T3/pl unknown
- 2005-09-20 WO PCT/EP2005/010119 patent/WO2006034797A1/en active Application Filing
- 2005-09-20 CN CN2005800407750A patent/CN101065360B/zh active Active
- 2005-09-20 SG SG200906448-6A patent/SG155996A1/en unknown
- 2005-09-20 KR KR1020127030937A patent/KR101381454B1/ko active Active
- 2005-09-20 CA CA2581843A patent/CA2581843C/en active Active
- 2005-09-20 KR KR1020077007003A patent/KR20070058537A/ko not_active Ceased
- 2005-09-20 EP EP05797740A patent/EP1797038B1/en not_active Revoked
- 2005-09-20 KR KR1020107011544A patent/KR101239489B1/ko active Active
- 2005-09-20 KR KR1020097001647A patent/KR20090018224A/ko not_active Ceased
- 2005-09-20 AU AU2005289100A patent/AU2005289100B2/en active Active
- 2005-09-20 UA UAA200704751A patent/UA91520C2/ru unknown
- 2005-09-20 JP JP2007533905A patent/JP5215666B2/ja active Active
- 2005-09-20 SI SI200531571T patent/SI1797038T1/sl unknown
- 2005-09-20 DK DK05797740.7T patent/DK1797038T3/da active
- 2005-09-20 BR BRPI0515946-6A patent/BRPI0515946A/pt not_active Application Discontinuation
- 2005-09-20 PT PT05797740T patent/PT1797038E/pt unknown
- 2005-09-20 US US11/664,363 patent/US8877933B2/en active Active
- 2005-09-20 NZ NZ553804A patent/NZ553804A/en unknown
- 2005-09-26 AR ARP050104016A patent/AR051301A1/es not_active Application Discontinuation
- 2005-09-27 MY MYPI20054554A patent/MY176929A/en unknown
- 2005-09-28 UY UY29144A patent/UY29144A1/es not_active Application Discontinuation
- 2005-09-28 PE PE2005001145A patent/PE20060699A1/es not_active Application Discontinuation
- 2005-09-28 PE PE2009001132A patent/PE20100445A1/es not_active Application Discontinuation
- 2005-09-28 GT GT200500270A patent/GT200500270A/es unknown
- 2005-09-28 TW TW094133622A patent/TWI382016B/zh active
- 2005-09-28 PE PE2014000731A patent/PE20142042A1/es active IP Right Grant
- 2005-09-29 HN HN2005000722A patent/HN2005000722A/es unknown
2007
- 2007-03-06 IL IL181734A patent/IL181734A/en unknown
- 2007-03-22 NO NO20071508A patent/NO344272B1/no unknown
- 2007-03-26 CU CU20070068A patent/CU20070068A7/es unknown
- 2007-03-27 ZA ZA200702510A patent/ZA200702510B/xx unknown
- 2007-03-28 EC EC2007007356A patent/ECSP077356A/es unknown
- 2007-03-29 MA MA29784A patent/MA28880B1/fr unknown
2008
- 2008-04-22 HK HK08104454.3A patent/HK1114605A1/xx not_active IP Right Cessation
2012
- 2012-08-16 HR HRP20120662TT patent/HRP20120662T1/hr unknown
- 2012-08-24 CY CY20121100767T patent/CY1113598T1/el unknown
- 2012-12-20 JP JP2012278376A patent/JP2013100302A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
KR20070058537A (ko)	2007-06-08
CN101065360A (zh)	2007-10-31
KR20130004385A (ko)	2013-01-09
EP1797038A1 (en)	2007-06-20
UA91520C2 (en)	2010-08-10
ECSP077356A (es)	2007-04-26
KR20090018224A (ko)	2009-02-19
PE20142042A1 (es)	2014-12-03
HK1114605A1 (en)	2008-11-07
TWI382016B (zh)	2013-01-11
US8877933B2 (en)	2014-11-04
ZA200702510B (en)	2008-07-30
SI1797038T1 (sl)	2012-10-30
CA2581843A1 (en)	2006-04-06
KR101381454B1 (ko)	2014-04-04
AU2005289100B2 (en)	2011-11-03
JP5215666B2 (ja)	2013-06-19
CU20070068A7 (es)	2010-01-22
US20090215833A1 (en)	2009-08-27
NO344272B1 (no)	2019-10-21
EP1797038B1 (en)	2012-06-13
MY176929A (en)	2020-08-27
NZ553804A (en)	2010-07-30
PT1797038E (pt)	2012-08-14
AR051301A1 (es)	2007-01-03
KR20100061869A (ko)	2010-06-09
GT200500270A (es)	2006-04-25
IL181734A (en)	2015-10-29
DK1797038T3 (da)	2012-09-03
HRP20120662T1 (hr)	2012-09-30
JP2008514658A (ja)	2008-05-08
ES2387812T3 (es)	2012-10-02
HN2005000722A (es)	2010-08-19
MA28880B1 (fr)	2007-09-03
PE20060699A1 (es)	2006-08-12
CA2581843C (en)	2012-05-15
KR101239489B1 (ko)	2013-03-06
SG155996A1 (en)	2009-10-29
IL181734A0 (en)	2007-07-04
CY1113598T1 (el)	2016-06-22
BRPI0515946A (pt)	2008-08-12
TW200626552A (en)	2006-08-01
AU2005289100A1 (en)	2006-04-06
PE20100445A1 (es)	2010-07-04
UY29144A1 (es)	2006-04-28
NO20071508L (no)	2007-06-22
JP2013100302A (ja)	2013-05-23
WO2006034797A1 (en)	2006-04-06
CN101065360B (zh)	2011-08-03

Publication	Publication Date	Title
IL181734A0 (en)	2007-07-04	Thermodynamically stable form of bay 43-9006 tosylate
HRP20182133T1 (hr)	2019-03-22	Pripravci koji sadrže azelastin i postupci njihove upotrebe
PL1802579T3 (pl)	2014-04-30	Pochodne 3-aryloaminopirydynowe
SG119330A1 (en)	2006-02-28	Improved shirttails for reducing damaging effects of cuttings
EP1832731A4 (en)	2013-11-27	COOLING STRUCTURE OF CONSTRUCTION EQUIPMENT
EP1756092A4 (en)	2009-12-02	NEW INHIBITORS OF RHO-KINASEN
HK1109332A1 (zh)	2008-06-06	藻毒素的經皮給藥
GB0409354D0 (en)	2004-06-02	Removal of needles
GB0708824D0 (en)	2007-06-20	Improved underreamer and method of use
ZA200705011B (en)	2010-01-27	Formulations of substituted benzoxazoles
HK1098122A1 (en)	2007-07-13	Stereoselective synthesis of vitamin d analogues
GB0419514D0 (en)	2004-10-06	Cooling of pump rotors
GB0421176D0 (en)	2004-10-27	Treatment of atherosclerosis
GB2420274B (en)	2007-10-17	Shaft structure of foldable unbrella
HUE037787T2 (hu)	2018-09-28	Alfa-mannozidáz gyógyászati alkalmazása
HU3005U (en)	2005-10-28	Mechanical stripper for bearing for rotors and bearing
PL369353A1 (pl)	2006-02-06	Zestaw elementów budowlanych
GB0412882D0 (en)	2004-07-14	New formulation of eletriptan
GB0422195D0 (en)	2004-11-03	Cooling of pump rotors
GB0425726D0 (en)	2004-12-22	Removal wedges
GB0406358D0 (en)	2004-04-21	Aircraft personal audio interface